


Claims

1. 1,2,3,4-tetrahydroisoquinoline derivatives of the general formula (I)



(I)

wherein:

- 5  $R^1$  and  $R^2$  independently represent hydrogen or  $C_1$ - $C_4$  alkoxy;

$R^3$  represents  $C_1$ - $C_6$ -alkyl;

X represents -CH- or a nitrogen atom;

and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of  
10 diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts, solvent complexes and morphological forms, thereof.

2. 1,2,3,4-tetrahydroisoquinoline derivatives according to claim 1 wherein  $R^1$  and  $R^2$  both represent a  $C_1$ - $C_4$  alkoxy group.
3. 1,2,3,4-tetrahydroisoquinoline derivatives according to claim 2 wherein  $R^1$  and  $R^2$  both represent a methoxy group.
- 15 4. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1 to 3 wherein X represents a nitrogen atom.
5. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1 to 3 wherein X represents -CH-.
- 20 6. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1 to 5 wherein  $R^3$  represents a methyl group.
7. 1,2,3,4-tetrahydroisoquinoline derivatives according to any of claims 1, 2, 3 or 5 wherein  $R^1$  and  $R^2$  represent a methoxy group, X represents -CH- and  $R^3$  represents  $C_1$ - $C_6$ -alkyl.

8. A 1,2,3,4-tetrahydroisoquinoline derivative according to any of the claims 1 to 3 selected from the group consisting of:
- 2-{6,7-Dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1*H*-iso-quinolin-2-yl}-*N*-methyl-2-phenyl-acetamide;
- 5 2-{6,7-Dimethoxy-1-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro-1*H*-iso-quinolin-2-yl}-*N*-methyl-2-phenyl-acetamide.
9. A 1,2,3,4-tetrahydroisoquinoline derivative according to any of the preceding claims for use as medicament.
10. A pharmaceutical composition containing at least one compound according to any of claims 1 to 8 and a pharmaceutically acceptable carrier material.
11. Use of a 1,2,3,4-tetrahydroisoquinoline derivative according to any of claims 1 to 8 in the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Tourette syndrome; diabetes; appetite/taste disorders; vomiting/nausea; asthma; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Froehlich's syndrome; hypophysis diseases, hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to infection e.g. by HIV; post-chemotherapy pain; post-

- stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; eating disorders; cardiovascular disorders; neurodegenerative disorders; sleep apnea; narcolepsy; insomnia; parasomnia; and neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy, seizure disorders and other diseases related to general orexin system dysfunctions.
- 5
12. Use according to claim 11 wherein said diseases are selected from the group consisting of eating disorders or sleep disorders.
- 10
13. Use according to claim 12 wherein said eating disorders comprise metabolic dysfunction, dysregulated appetite control, compulsive obesities, emeto-bulimia or anorexia nervosa.
14. Use according to claim 12 wherein said sleep disorders comprise insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome.
- 15